Dr. Bing Zhao 赵兵
Chief Physician, Associate Professor
Department of Medical Oncology, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, and rehabilitation guidance for breast cancer.
Dr. Zhao has over twenty years of clinical experience in the diagnosis, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, and rehabilitation guidance for breast cancer.
Name order: in Chinese the family name comes first (Zhao Bing). Papers usually list the name as Bing Zhao or Zhao B.
Selected publications
30 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Pharmacol, 2026 (senior author): Real-world comparative outcomes of pyrotinib-based versus pertuzumab-based first-line therapy in HER2-Positive advanced breast cancer: a multicenter retrospective cohort study from Xinjiang, China. PubMed 42959174
- Front Oncol, 2026 (senior author): Efficacy and safety of dalpiciclib combined with endocrine therapy in elderly patients with HR(+)/HER2(-) advanced breast cancer: a real-world study. PubMed 42682505
- Eur J Histochem, 2026 (first author): Histopathological evaluation of RPL5 expression in triple-negative breast cancer: an integrated immunohistochemical and transcriptomic study. PubMed 42489642
- Transl Cancer Res, 2025 (senior author): Clinical efficacy and safety of pyrotinib as the first-line treatment of HER2-positive advanced breast cancer in Xinjiang Uygur Autonomous Region of China. PubMed 41378017
- Front Oncol, 2025 (senior author): Clinical characteristics and prognosis of breast cancer patients with ovarian metastases. PubMed 41064097
- BMC Med Inform Decis Mak, 2025 (senior author): Clinicopathological observation and prognostic factors of invasive breast cancer with medullary in Xinjiang. PubMed 40604782
- Cancer Med, 2024 (senior author): Prognostic and Predictive Markers for Early Stage Triple-Negative Breast Cancer Treated With Platinum-Based Neoadjuvant Chemotherapy. PubMed 39445528
- Exp Biol Med (Maywood), 2023 (senior author): Pyrotinib combining with radiotherapy on breast cancer with brain metastasis. PubMed 36533572
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion